Cybin Inc. (OTCMKTS:CYBN - Get Free Report) was down 5.7% during mid-day trading on Monday . The stock traded as low as $6.20 and last traded at $6.34. Approximately 269,681 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 261,761 shares. The stock had previously closed at $6.72.
Cybin Price Performance
The company has a market cap of $128.00 million, a PE ratio of -31.37 and a beta of 0.61. The firm has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $9.17.
Cybin Company Profile
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
